PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh PC1, Harview CL2, Yearley JH3, Shintaku IP2, Taylor EJ2, Robert L2, Chmielowski B1, Spasic M2, Henry G2, Ciobanu V2, West AN2, Carmona M2, Kivork C2, Seja E2, Cherry G2, Gutierrez AJ2, Grogan TR2, Mateus C4, Tomasic G4, Glaspy JA1, Emerson RO5, Robins H6, Pierce RH3, Elashoff DA1, Robert C4, Ribas A1. 1University of California Los Angeles (UCLA), Los Angeles, California 90095, USA [2] Jonsson Comprehensive Cancer Center, Los Angeles, California 90095, USA. 2University of California Los Angeles (UCLA), Los Angeles, California 90095, USA. 3Merck &Co, Palo Alto, California 94304, USA. 4Gustave Roussy and INSERM U981, Villejuif, Paris Sud, France. 5Adaptive Biotechnologies, Seattle, Washington 98102, USA. 6Adaptive Biotechnologies, Seattle, Washington 98102, USA [2] Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.